Seres Therapeutics Stock Fundamentals
| 1S9 Stock | EUR 0.83 0.05 5.68% |
Seres Therapeutics fundamentals help investors to digest information that contributes to Seres Therapeutics' financial success or failures. It also enables traders to predict the movement of Seres Stock. The fundamental analysis module provides a way to measure Seres Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seres Therapeutics stock.
Seres |
Seres Therapeutics Company Shares Outstanding Analysis
Seres Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Seres Therapeutics Shares Outstanding | 124.59 M |
Most of Seres Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seres Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Seres Therapeutics has 124.59 M of shares currently outstending. This is 30.99% lower than that of the Healthcare sector and 16.6% higher than that of the Biotechnology industry. The shares outstanding for all Germany stocks is 78.21% higher than that of the company.
Seres Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Seres Therapeutics's current stock value. Our valuation model uses many indicators to compare Seres Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Seres Therapeutics competition to find correlations between indicators driving Seres Therapeutics's intrinsic value. More Info.Seres Therapeutics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seres Therapeutics' earnings, one of the primary drivers of an investment's value.Seres Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seres Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics of similar companies.Seres Therapeutics is currently under evaluation in shares outstanding category among its peers.
Seres Fundamentals
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (17.02) % | |||
| Current Valuation | 582.79 M | |||
| Shares Outstanding | 124.59 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 85.90 % | |||
| Price To Book | 12.02 X | |||
| Price To Sales | 50.23 X | |||
| Revenue | 144.93 M | |||
| Gross Profit | 3.04 M | |||
| EBITDA | (56.72 M) | |||
| Net Income | (65.58 M) | |||
| Cash And Equivalents | 253.62 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 24.64 M | |||
| Debt To Equity | 0.23 % | |||
| Current Ratio | 5.79 X | |||
| Book Value Per Share | 0.54 X | |||
| Cash Flow From Operations | 6.69 M | |||
| Earnings Per Share | (2.18) X | |||
| Target Price | 20.57 | |||
| Number Of Employees | 333 | |||
| Beta | 2.68 | |||
| Market Capitalization | 608.32 M | |||
| Total Asset | 354.86 M | |||
| Z Score | 14.4 | |||
| Net Asset | 354.86 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.